Global Nicotine Gum Market - 2023-2030

Global Nicotine Gum Market - 2023-2030

The Global Nicotine Gum Market reached US$ 1.2 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 1.8 billion by 2030. The market is growing at a CAGR of 5.7% during the forecast period 2023-2030. An FDA-approved drug that can assist people in quitting smoking is nicotine gum. It can be used as needed for stronger cravings or every two hours in conjunction with a nicotine patch to prevent withdrawal symptoms which drives the nicotine market size.

Additionally, the gum is a member of the group of drugs known as smoking cessation aids. It is a kind of flavoured chewing gum that releases nicotine into the mouth lining, where it is then absorbed into the smoker's bloodstream and suppresses his or her urge to smoke. Health organisations like the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) have advised smokers to give up smoking as a preventative measure in order to recover from COVID-19 infection as a result people started consuming nicotine gum.

Nicotine delivery and absorption play a crucial role in nicotine addiction. Withdrawal symptoms can arise when attempting to quit, as the body becomes dependent on nicotine. Nicotine gum, with its varied flavors, offers a controlled dosing method and aids in managing nicotine withdrawal while enhancing the quitting experience, therbey driving the nicotine gum market size.

Market Dynamics

Promotion of Anti-Smoking Campaigns Drives the Market Expansion.

The growth of this market is propelled by several factors including increasing urbanization, continuous product innovations such as the development of nicotine gums, and extensive research and development efforts. Governments and non-governmental organizations (NGOs) in both emerging and developed nations actively promote the use of smoking cessation products, including nicotine gums and other nicotine replacement products, to help individuals, especially young people, overcome tobacco addiction.

Key players in the industry consistently support anti-smoking campaigns and regularly introduce smoking cessation items like gums and lozenges. By combining these products with effective quit programs, the likelihood of successful smoking cessation among individuals is significantly enhanced. For instance, on February 18, 2022, Betapharm Arzneimittel GmbH, Enorama Pharma's business partnered and launched a generic nicotine chewing gum called Nicotine Beta in Germany. This brand focuses on generic products that emphasize the benefits of nicotine replacement therapy (NRT).

The Increasing Prevalence of Illness Boosts the Usage of Nicotine Gum.

The increasing awareness of the health risks associated with smoking has led to a surge in the number of individuals attempting to quit smoking, which is a significant driver of market growth. Additionally, there has been a notable increase in demand for nicotine cessation products from rehabilitation clinics and medical institutions in both developed and developing countries worldwide. Furthermore, the market is primarily propelled by the growing prevalence of specific illnesses such as lung cancer, cardiac diseases, and respiratory disorders, which are often linked to tobacco use and pose a significant public health burden globally. These factors contribute to the potential growth of the nicotine gum market.

The Side Effects Associated With Nicotine Gum Hamper the Expansion of the Market.

High blood pressure, dizziness, a rapid heartbeat, insomnia, irritability, indigestion, heartburn, loss of appetite, vomiting, and hiccups are some of the common side effects of nicotine gum. Additionally, it induces nausea and abdominal discomfort when chewed frequently and for a long time. Therefore, it is anticipated that this factor will restrain market growth during the forecast period.

COVID-19 Impact Analysis

The COVID-19 Analysis includes Pre-COVID Scenario, COVID Scenario and Post-COVID Scenario along with Pricing Dynamics (Including pricing change during and post-pandemic comparing it with pre-COVID scenarios), Demand-Supply Spectrum (Shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), Government Initiatives (Initiatives to revive market, sector or Industry by Government Bodies) and Manufacturers Strategic Initiatives (What manufacturers did to mitigate the COVID issues will be covered here).

Artificial Intelligence Analysis

Artificial intelligence (AI) analysis on nicotine gum can offer valuable insights into its effectiveness, user experiences, safety profile, and comparative analysis. By analyzing scientific studies, clinical trials, user feedback, and social media data, AI algorithms can evaluate the efficacy of nicotine gum in aiding smoking cessation and optimizing dosage recommendations. AI can also assess user sentiment, identify potential side effects, and compare different brands or formulations of nicotine gum. Additionally, AI can develop predictive models to personalize treatment plans and predict outcomes for individuals considering nicotine gum as a smoking cessation aid. While AI analysis provides valuable information, it should be complemented by medical expertise and not replace professional advice.

Segment Analysis

The global nicotine gum market is segmented based on type, application, distribution channel and region.

By Type, the 2mg Segment is Estimated to Have Significant Growth During the Forecast Period

Due to its advantages for light smokers who use fewer than 25 cigarettes per day, the 2mg market category enjoys a substantial market share. Potential customers are still drawn to the readily available 2mg nicotine gums in a range of flavors, which appears to be allowing growth to pick up speed over the predicted period. The effects of nicotine withdrawal and tobacco cravings are reduced and controlled by Nicorette 2mg gum. It is advised to help smokers who try to quit or lower their risk of doing so, to support smokers who are hesitant or unable to stop, and to act as a reasonably safe smoking alternative for both smokers and others around them.

Geographical Analysis

North America is the Fastest Growing Market in the Nicotine Gum Market

In North America, nicotine gum is a popular choice for individuals seeking to quit smoking. With its convenient availability over-the-counter, nicotine gum offers a discreet and accessible form of nicotine replacement therapy (NRT). This region has witnessed a growing demand for nicotine gum as part of smoking cessation efforts, as it provides a convenient and portable option for managing nicotine cravings and withdrawal symptoms.

Additionally, the availability of various nicotine gum flavors in North America caters to diverse preferences, further contributing to its popularity among those looking to quit smoking in the region. For instance, on May 17, 2021, North America Generics, Dr. Reddy’s Laboratories, launched 2 mg and 4 mg, the store brand version of Nicorette Lozenges in the U.S. With the introduction of Nicotine Polacrilex Lozenges, the OTC category of smoking cessation products is still committed

Competitive Landscape

The major global players in the market include Cipla Health Limited, Perrigo Company Plc., Teva Canada, Philip Morris, British American Tobacco PLC, Johnson & Johnson, Novartis AG, ITC Limited, Major Pharmaceuticals Inc. and Lil Drug Store Products Inc.

Why Purchase the Report?
• To visualize the global nicotine gum market segmentation based on type, application, distribution channel and region, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities in the market by analyzing trends and co-development.
• Excel data sheet with numerous data points of nicotine gum market-level with all segments.
• The PDF report consists of cogently put-together market analysis after exhaustive qualitative interviews and in-depth market study.
• Product mapping is available as Excel consists of key products of all the major market players.

The global nicotine gum market report would provide approximately 61 tables, 58 figures and 190 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies